NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.

More than half of EU adults are overweight, while one in six is classified as obese; it’s a growing problem for healthcare ...

The financial website Wallethub compared all 50 states and the District of Columbia to rank the most overweight and obese ...

The rising obesity trend is seriously worrying and requires urgent, dedicated and consistent intervention on both micro and macro scales.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Parents in Wiltshire might want to put the chocolates on a high shelf and keep an eye on the fizzy drinks this Christmas, ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

There is an increase in the number of referrals of children with obesity, growing waiting lists, and significantly more ...

A major review in Frontiers in Science highlights how tackling unsustainable food systems—reflected by our changing food ...

Vets are exploring new medicines for overweight cats. These drugs mimic hormones that reduce appetite and improve glucose ...

“Early intervention would be lifestyle change, and that can be extremely helpful, especially in younger adolescents who are ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...